Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models.

Abstract

Pseudomonas aeruginosa is a challenge for clinicians due to increasing drug resistance and dwindling treatment options. We report on the activity of MEDI3902, an antibody targeting type 3 secretion protein PcrV and Psl exopolysaccharide, in rabbit bloodstream and lung infection models. MEDI3902 prophylaxis or treatment was protective in both acute models and exhibited enhanced activity when combined with a subtherapeutic dose of meropenem. These findings further support MEDI3902 for the prevention or treatment of serious P. aeruginosa infections.

• Authors: Hoan N Le, Vuvi G Tran, Trang T T Vu, Emmanuelle Gras, Vien T M Le, Marcos Gabriel Pinheiro, Fábio Aguiar-Alves, Erika Schneider-Smith, Henry Clay Carter, Bret R Sellman, C Kendall Stover, Antonio DiGiandomenico, Binh An Diep
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 63 Issue 8 (08 2019) ISSN: 1098-6596 [Electronic] United States
• PMID: 31160288 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2019 Le et al.

Chemical References

• Antibodies, Bispecific
• gremubamab
• Meropenem

Topics

• Animals
• Antibodies, Bispecific (therapeutic use)
• Bacteremia (drug therapy, microbiology, therapy)
• Immunotherapy
• Meropenem (therapeutic use)
• Pneumonia (drug therapy, microbiology, therapy)
• Pseudomonas Infections (drug therapy, microbiology, therapy)
• Pseudomonas aeruginosa (drug effects, pathogenicity)
• Rabbits
• Treatment Outcome